AtriCure has received an expanded indication for the AtriClip left atrial appendage (LAA) exclusion system in CE-marked countries in Europe.
The product is now indicated for use in patients at high risk of thromboembolism for whom LAA exclusion is warranted.
The AtriClip family of devices are designed to exclude, electrically isolate and eventually eliminate the LAA—a major source of blood clots in patients with atrial fibrillation (AF)—during cardiac surgery.
“This new indication is tremendous validation of our AtriClip device,” said Michael Carrel, president and chief executive officer of AtriCure. “With over 550,000 patients successfully treated worldwide, we have seen the impact that our devices have on patient care. The expanded indication from the European Commission confirms our own clinical evidence that strokes can be reduced in patients who are at high risk of developing thromboembolism, and we continue to see strong opportunity to grow adoption of mechanical appendage closure.”
“I’ve been using AtriClip devices for over a decade and have seen firsthand the benefits of its safety and efficacy,” said Nicolas Doll (Schuechtermann Clinic, Bad Rothenfelde, Germany). “The devices are easy to use, and they provide patients with the benefit of long-term prevention of stroke, which makes adoption of the AtriClip an easy decision.”
